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Hepatitis  A  virus  (HAV)  infection  usually  spreads 
through the fecal-oral route. It is an acute, self-limiting 
disease with a mild course that is often silent in pedi-
atric cases. However, this infection can be more severe 
and  even  fatal  in  older  individuals.  It  usually  has  an 
uncomplicated course; however, complications such as 
cholestatic  hepatitis,  relapsing  hepatitis,  extrahepatic 
manifestations, or rarely, fulminant hepatitis and even 
death may occur. These complications are more preva-
lent in adults, especially those more than 40 years of age. 
Superimposed  infection  in  patients  with  chronic  liver 
disease, particularly hepatitis B or hepatitis C infection, 
may accentuate the disease course and cause acute liver 
failure (1). The rate of spread and prevalence of infection 
in each community depends on the hygiene conditions 
and sanitation status. Because the virus sheds as early 
as 2 weeks prior to the onset of jaundice, the disease can 
be  transmitted  by  asymptomatic  persons  during  the 
incubation period of the virus. Three strategies for HAV 
prevention have been suggested in high-risk groups. The 
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 Implication for health policy/practice/research/medical edu-
cation:
In order to emphasize the importance of HAV prevalence in nor-
mal population, we invite all researcher to read this article espe-
cially who are involved for making health policies.
first strategy is personal hygiene and enteric isolation, 
including hand washing after close contact. The second 
strategy is passive immunoprophylaxis via injection of 
human serum immunoglobulin derived from subjects 
with high HAV antibody levels. The third route is vacci-
nation, which is usually performed before exposure, but 
can also be performed in the early post-exposure period 
in outbreaks (2). 
Active immunoprophylaxis by vaccination is the most 
important strategy for preventing disease at the nation-
al level. To implement a national HAV vaccination cam-
paign, the cost and an epidemiological survey for this 
infection should be considered (3). Vaccination is very 
effective for preventing this disease; however, due to lim-
ited health budgets, evaluation of the cost-effectiveness 
in each region is very important. In Middle East countries 
with  high  or  intermediate  HAV  infection  prevalence, 
multiple strategies can be implemented to prevent HAV 
infection.  The  success  of  routine  vaccination,  acceler-
ated vaccinations in outbreaks, ongoing vaccination of 
children,  and  outbreak-control  vaccination  programs 
largely  depends  on  the  feasibility  of  rapidly  vaccinat-
ing  the  target  population  (2).  Proper  decision-making 
regarding the need for national vaccination depends on 
the prevalence and incidence of HAV infection. In this is-Hepat Mon. 2011;11(4):235-237
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sue of Hepatitis Monthly, Taghavi et al. have reported the 
prevalence of HAV infection in unmarried young adults 
in the Fars province of southern Iran (4). 
In this study, 88.2% of 1050 subjects were seropositive 
for the anti-HAV antibody, whereas 11.8% were negative 
for it. Anti-HAV antibody positivity was observed in 79.3% 
of subjects < 20 years old and 99% of those > 30 years 
old (p = 0.01). Anti-HAV positivity was significantly more 
frequent in individuals living in rural regions (95.9% of 
individuals in rural regions vs. 85.1% of individuals living 
in  urban  areas).  Family  crowding  was  associated  with 
higher antibody levels.   Previously, Iran was considered 
to have a high rate of HAV infection. However, because 
the hygiene conditions, sanitation status, and education 
levels have improved dramatically in the last 2 decades, 
lower rates of infection have been observed (5). Despite 
high rate of HAV infection in most studies from different 
counties, in some studies very low rate of exposure was 
reported, which may be due to inclusion of children and 
adolescent and young adult groups.
The rate of seropositivity for anti-HAV IgG has varied 
from 8.6% among 816 subjects between the age of 6 and 
>50 years (6), up to 22.3% among 1018 children aged 6 
months to 14.9 years in Tehran (7), 61.6% among 1065 sub-
jects aged 6 months to 20 years (8), 44.3% among 300 chil-
dren in Zanjan (9), 50% in Tehran (10), 68% in Shiraz (11), 
86.8% in Golestan (12), 89.5% in Yazd (13), 84.9% in Sari (14), 
98.6% in Golestan (15), 94.9% in Qazvin (16), 86% in Tehran 
(17), and 97.63% in soldiers in Tehran (18). Merat and col-
leagues performed a serological assay to determine the 
prevalence of HAV infection among 1896 subjects aged 18 
to 65 years in Tehran, Golestan in the north, and Hormoz-
gan in the south, and overall, 86% of the subjects were 
positive for anti-HAV IgG. The rate of infection in younger 
subjects in urban areas was 70% (19).
Patients with chronic liver disease may experience ex-
acerbation of liver disease and even a fatal clinical course 
if a superimposed HAV infection occurs. The rate of HAV 
immunity in patients with chronic liver disease has been 
determined in a few studies. In 3 studies, the rates of anti-
HAV seropositivity were greater than 95% in patients aged 
> 30 years, 71.4% in patients aged 10–20 years, and 59.4% 
in patients aged 10–20 years (20-22). Mhoghani et al. re-
ported a 80% rate of HAV immunity in chronic hepatitis B 
patients with different stages of disease. The mean age of 
patients with anti-HAV positivity (40.91 ± 12.91 years) was 
significantly higher than that of patients with negative 
antibody status (33.49 ± 12.88 years, p = 0.000). They sug-
gested vaccination in patients with chronic liver disease 
(23). 
The  improvement  of  sanitation  and  national  health 
programs in some countries in the Middle East and Asia 
reduced the rate of HAV infection in children, and as a re-
sult, more young adults are prone to this infection. This 
has been observed in many communities as the epidemi-
ology of HAV shifted from a hyperendemic to a hypoen-
demic pattern. In a report from India, in 1932 patients 
with acute viral hepatitis, 11.4% of the cases were related 
to HAV. Over a 5-year period, the rate of infection in chil-
dren increased from 10.6% to 22.0% and the rate of infec-
tion in adultsincreased from 3.4% to 12.3% (24). 
According to a report from South Korea, the rate of anti-
HAV antibody positivity has decreased, and the rate of 
acute HAV infection has increased in subjects aged 10–50 
years during the past 3 decades (25). In a multi-center 
study from Lebanon, HAV seroprevalence was 78% in sub-
jects ≥ 21 years, 28% in subjects aged 6–10 years, and 11% 
in subjects aged 1–5 years. Due to the low rate of HAV im-
munity and more severe form of HAV infection in adults 
and children, the authors concluded that a national vac-
cination campaign was required (26). Some reports have 
indicated an increasing rate of acute HAV infection in 
adults in Iran in recent years (27-29). Reports in our coun-
try and others in Asia implied that HAV infection will be 
an important health problem in the future. Health status 
differences  among  neighbors  traveling  between  these 
countries may result in the transmission of hepatitis to 
susceptible subjects (30). As a whole, the findings imply 
that in the near future, more cases of acute HAV infection 
in children and adults will be reported. HAV infection 
can be effectively prevented by HAV vaccines (31). 
Generally, susceptibility to HAV infection is higher in 
people younger than 20 years old both for healthy sub-
jects and for patients with chronic liver disease. Consid-
ering the increased susceptibility of young and adults 
to acute HAV infection in Asian countries, some sugges-
tions can be proposed. First, the available data should be 
discussed by a team of experts. If needed, well-designed 
surveys should be performed to estimate the exact preva-
lence and incidence of this viral illness in our commu-
nity. Second, according to the present data and/or future 
research,  the  possible  benefits  of  national  childhood 
vaccination programs for viruses such as hepatitis B or 
a catch-up vaccination program for the high school age 
group should be considered. This strategy can effectively 
decrease the incidence of HAV infection. Some authors 
have suggested a possible benefit only in young subjects 
in selected urban regions and have not recommended 
routine vaccination of all people (19). Third, the health 
system  infrastructure  should  be  prepared  to  handle 
possible  outbreaks  at  daycare  centers  or  nurseries  or 
common source outbreaks such as those caused by con-
taminated foods or water. This event requires the early di-
agnosis of infected subjects and accelerated vaccination 
of  exposed  or  susceptible  persons.  Proper  vaccination 
of high-risk groups such as patients with chronic liver 
disease, especially those younger than 20–30 years old, is 
suggested. The Ministry of Health is urged to report HAV 
infection (clinical) rates to improve the interpretation of 
the HAV situation in our country. 
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